Saliva as a source of reagent to study human susceptibility to avian influenza H7N9 virus infection

Tan, Ming; Cui, Lunbiao; Xiang, Hao; Xia, Ming; Shi, Fengjuan; Zeng, Xianying; Huang, Pengwei; Zhong, Weiming; Li, Weiwei; Xu, Ke; Chen, Liling; Zhou, Minghao; Jiang, Xi

doi:10.1038/s41426-018-0160-8

Cited by 9 publications

(6 citation statements)

References 27 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have proved the concept by generating a chimeric S-VP8* nanoparticle that contains 60 displayed rotavirus neutralizing antigen VP8*s on the surface of the self-assembled S particles [17]. A similar principle has also been used for making S-HA1 particles that display the HA1 antigens of the H7N9 influenza virus [18].…”

Section: Introductionmentioning

confidence: 93%

Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice

Xia

Huang

Jiang

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

Rotaviruses cause severe diarrhea in infants and young children, leading to significant morbidity and mortality. Despite implementation of current rotavirus vaccines, severe diarrhea caused by rotaviruses still claims ~200,000 lives of children with great economic loss worldwide each year. Thus, new prevention strategies with high efficacy are highly demanded. Recently, we have developed a polyvalent protein nanoparticle derived from norovirus VP1, the S particle, and applied it to display rotavirus neutralizing antigen VP8* as a vaccine candidate (S-VP8*) against rotavirus, which showed promise as a vaccine based on mouse immunization and in vitro neutralization studies. Here we further evaluated this S-VP8* nanoparticle vaccine in a mouse rotavirus challenge model. S-VP8* vaccines containing the murine rotavirus (EDIM strain) VP8* antigens (S-mVP8*) were constructed and immunized mice, resulting in high titers of anti-EDIM VP8* IgG. The S-mVP8* nanoparticle vaccine protected immunized mice against challenge of the homologous murine EDIM rotavirus at a high efficacy of 97% based on virus shedding reduction in stools compared with unimmunized controls. Our study further supports the polyvalent S-VP8* nanoparticles as a promising vaccine candidate against rotavirus and warrants further development.

show abstract

Section: Introductionmentioning

confidence: 93%

Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice

Xia

Huang

Jiang

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Saliva samples from healthy employees in the Cincinnati Children’s Hospital Medical Center collected for studies of norovirus and rotavirus binding profiles of host histo blood group antigens in our previous studies [ 17 , 18 ] were used. Recombinant H7N9 and 1918 H1N1 HAs were constructed and expressed as described previously [ 16 ]. The 95 tested saliva sample donors were sorted based on the OD binding signals of H7N9 HA (top panel).…”

Section: Introductionmentioning

confidence: 99%

“…The H1 225G subtype viruses are responsible for the severe pathogenicity and high fatality of the 1918 pandemic. We first formulated the hypothesis of polymorphic 2,3-Sias in humans after finding that only ~30% of human subjects revealed ELISA binding signals in their saliva specimens by a recombinant HA of the avian H7N9 viruses that bind 2,3-but not 2,6-linked Sias [16]. Our further studies of saliva specimens from a panel of healthy adults confirmed the results with ~24% the saliva panel binding to the H7 HA antigens but, by comparison, 100% of the saliva panel revealed binding signals with a recombinant 1918 H1 antigen that is known to recognize 2,6-Sias (Fig 1).…”

Section: Introductionmentioning

confidence: 99%

Intra-species sialic acid polymorphism in humans: a common niche for influenza and coronavirus pandemics?

Jiang

Tan

Xia

et al. 2021

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

The ongoing COVID-19 pandemic has led to more than 159 million confirmed cases with over 3.3 million deaths worldwide, but it remains mystery why most infected individuals (∼98%) were asymptomatic or only experienced mild illness. The same mystery applies to the deadly 1918 H1N1 influenza pandemic, which has puzzled the field for a century. Here we discuss dual potential properties of the 1918 H1N1 pandemic viruses that led to the high fatality rate in the small portion of severe cases, while about 98% infected persons in the United States were self-limited with mild symptoms, or even asymptomatic. These variations now have been postulated to be impacted by polymorphisms of the sialic acid receptors in the general population. Since coronaviruses (CoVs) also recognize sialic acid receptors and cause severe acute respiratory syndrome epidemics and pandemics, similar principles of influenza virus evolution and pandemicity may also apply to CoVs. A potential common principle of pathogen/host co-evolution of influenza and CoVs under selection of host sialic acids in parallel with different epidemic and pandemic influenza and coronaviruses is discussed.

show abstract

“…As the natural barrier, it has been proved that the soluble salivary proteins glycosylated with terminal α2-3/6-linked Sia can neutralize and inhibit influenza viruses in this way efficiently [22][23][24]. And the protein sialylation level in saliva has been expected to be used as an indicator to estimate the individual susceptibility to influenza virus [25].…”

Section: Introductionmentioning

confidence: 99%

High Expression Level of α2-3-Linked Sialic Acids on Salivary Glycoproteins of Breastfeeding Women May Help to Protect Them from Avian Influenza Virus Infection

et al. 2022

View full text Add to dashboard Cite

Terminal sialic acids (Sia) on soluble glycoprotein of saliva play an important role in the clearance of influenza virus. The aim of this study is to investigate the alteration of sialylation on the salivary proteins of women during the lactation period and its effect on the saliva binding ability to virus. In total, 210 saliva samples from postpartum women with and without breastfeeding were collected, and the expression level of α2-3/6-linked Sia on the whole salivary proteins and specific glycoproteins of IgA and MUC5B from different groups were tested and verified using lectin microarray, blotting analysis and ELISA based method. The H1N1 vaccine and three strains of Avian influenza virus (AIV) were used for the saliva binding assay. Results showed that the variation in salivary expression level of α2-3-linked Sia was much more obvious than the α2-6-linked Sia, which was up-regulated significantly in the breastfeeding groups compared to the non-breastfeeding groups at the same postpartum stage. Furthermore, the binding abilities of salivary glycoproteins to AIV strains and H1N1 vaccine were increased in breastfeeding groups accordingly. This finding adds new evidence for the maternal benefit of breastfeeding and provides new thinking to protect postpartum women from AIV infection.

show abstract

Saliva as a source of reagent to study human susceptibility to avian influenza H7N9 virus infection

Cited by 9 publications

References 27 publications

Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice

Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice

Intra-species sialic acid polymorphism in humans: a common niche for influenza and coronavirus pandemics?

High Expression Level of α2-3-Linked Sialic Acids on Salivary Glycoproteins of Breastfeeding Women May Help to Protect Them from Avian Influenza Virus Infection

Contact Info

Product

Resources

About